NCT06608030

Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery

Effect of a Single Dose of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery: a Randomized Controlled Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 142 (actual)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, randomized controlled, blinded prospective study to investigate the effects of esketamine on perioperative anxiety and depression in patients undergoing cardiac valve surgery.

Detailed description

Undergoing surgery can be a traumatic and painful experience for patients, often causing negative moods such as anxiety and depression. The size and type of surgery significantly impact the occurrence of anxiety and depression in patients. Approximately one-third of patients after cardiac surgery experience anxiety or depression, which increases the risk of recurrent cardiovascular events and death. Ketamine is an anesthetic drug with comprehensive effects, including analgesia, sedation, and amnesia. Its primary mechanism of action is blocking N-methyl-D-aspartate (NMDA) receptors. Esketamine, the pure dextro isomer of ketamine, has a higher affinity for glutamate NMDA receptors and opioid receptors, offering stronger sedative, analgesic, and antidepressant effects. On March 4, 2019, esketamine was approved by the FDA for treatment-resistant depression. Given its analgesic, anesthetic, and antidepressant effects, esketamine may be an ideal drug for improving negative moods in patients undergoing cardiac surgery.

Conditions

• Depression, Anxiety
• Cardiac Surgery
• S-ketamine

Interventions

Type	Name	Description
DRUG	Esketamine	A single dose of 0.3mg / kg esketamine during induction of anesthesia.
DRUG	normal saline	Receiving the same volume of normal saline during induction of anesthesia.

Timeline

• Start date: 2024-09-23
• Primary completion: 2025-04-07
• Completion: 2025-04-30
• First posted: 2024-09-23
• Last updated: 2025-11-25

Locations

2 sites across 1 country: China